Valeant proposes Allergan deal

Article

Late yesterday afternoon, Valeant Pharmaceuticals announced that it had proposed a merger with Allergan.

 

Late yesterday afternoon, Valeant Pharmaceuticals announced that it had proposed a merger with Allergan.

Allergan’s largest shareholder (9.7%), Pershing Square Capital Management, managed by Bill Ackman, supports the initiative, according to Bloomberg. In addition, Mr. Ackman believes that Allergan is undervalued and worked with Valeant to cooperatively engage in a hostile takeover of Allergan.

Yesterday, according to the Wall Street Journal, Valeant offered Allergan $48.30 and 0.83 Valeant shares per Allergan share.

Allergan’s stock price was $116.63 on April 10, the day before Mr. Ackman began rapidly accumulating shares. It increased to $166.41 after news broke of Valeant’s interest.

Valeant finalized its acquisition of Bausch + Lomb in August 2013.ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jade Coats, OD, FAAO, gives her insight on what makes EyeCon valuable for eye care providers.
Allen, OD, FAAO, Dipl ABO, plans to talk all things ocular surface for optometrists and ophthalmologists alike.
Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz
© 2025 MJH Life Sciences

All rights reserved.